Table 1 Demographic of the study population (n = 67)

Sex (men:women), n

47:20

Age, years

 Men

62.2 ± 11.6 (40–86)^†

 Women

62.2 ± 13.3 (30–83)^†

Underlying disease, % (n/N)

 Chronic hepatitis B

40.3 (27/67)

 Chronic hepatitis C

10.4 (7/67)

 Alcoholic liver disease

19.4 (13/67)

 Cryptogenic

29.9 (20/67)

Laboratory findings

 Albumin, g/dL

4.3 ± 0.5 (2.6–5.2)^†

 Total bilirubin, mg/dL

0.9 ± 0.7 (0.3–4.1)^†

 INR

1.1 ± 0.2 (0.9–1.9)^†

 Platelet count, × 10³/mm³

146.1 ± 63.8 (42–317)^†

 AFP, ng/mL

329.4 ± 1699.6 (1.6–12,327)

Body weight, kg

65.1 ± 12.1 (39.6–96.6)^†

Mean body mass index, kg/m²

24.1 ± 3.8 (15.3–35.3)^†

DLP, mGycm

 Standard dose

848.8 ± 208.6 (423.0–1432.0)^†

 Low dose

568.7 ± 139.7 (296.1–1002.4)^†

 Ultra-low dose

280.1 ± 68.8 (126.9–429.6)^†

Effective dose (mSv)

 Standard dose

12.7 ± 3.1 (6.3–21.5)^†

 Low dose

8.5 ± 2.1 (4.4–15.0)^†

 Ultra-low dose

4.2 ± 1.0 (1.9–6.4)^†